PUMA BIOTECHNOLOGY, INC. (PBYI) Total liabilities 2017–2025
PUMA BIOTECHNOLOGY, INC. (PBYI) total liabilities at each fiscal year-end, per SEC filings.
$86.0MFY2025 · since FY2017: $112.2M → $86.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $86.0M | -29.1% |
| FY2024 | $121.2M | -31.6% |
| FY2023 | $177.1M | -11.7% |
| FY2022 | $200.5M | -12.5% |
| FY2021 | $229.0M | -8.5% |
| FY2020 | $250.2M | +15.1% |
| FY2019 | $217.4M | -3.3% |
| FY2018 | $224.8M | +100.3% |
| FY2017 | $112.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More PBYI financial trends
PBYI RevenuePBYI Net incomePBYI Net marginPBYI Gross profitPBYI Gross marginPBYI Operating incomePBYI Operating marginPBYI Operating cash flowPBYI Free cash flowPBYI Capital expendituresPBYI Return on equityPBYI Stock buybacksPBYI Dividends paidPBYI Total assetsPBYI Shareholders’ equityPBYI overview →